RET and lung adenocarcinoma: Another study has shown the good response of RET‐rearranged adenocarcinoma to cabozantinib, a multi‐kinase inhibitor.28 While fusion genes are rare events in lung adenocarcinoma, their presence is an indicator of possible targeted therapy.